Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich MD, Shah NR, Taylor TH, Page ST, Schiller SJ, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach PA. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLOS ONE 2022, 17: e0263591. PMID: 35213547, PMCID: PMC8880885, DOI: 10.1371/journal.pone.0263591.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsAntiviral AgentsCOVID-19 Drug TreatmentFemaleHumansMaleMiddle AgedRespiration, ArtificialTreatment OutcomeConceptsStandard of careSubcutaneous sarilumabMechanical ventilationSevere COVID-19 diseaseHospitalized COVID-19 patientsDays of randomizationIL-6R inhibitionRate of intubationTrial of patientsSevere COVID-19COVID-19 patientsNumber of patientsVA Medical CenterAnti-inflammatory drugsCOVID-19SARS-CoV-2COVID-19 diseaseData monitoring committeeEligible patientsPrimary endpointSOC armPrimary outcomeRespiratory compromiseElectronic health record systemsClinical criteria